FDA Approved Drugs for Infections and Infectious Diseases

Drugs Approved in 2017

Baxdela (delafloxacin) tablets and injection; Melinta Therapeutics; For the treatment of acute bacterial skin and skin structure infections, Approved June 2017

Benznidazole; Chemo Group; For the treatment of Chagas disease , Approved August 2017

Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] ; Dynavax; For the prevention of hepatitis B virus infection, Approved November 2017

KedRab [Rabies Immune Globulin (Human)]; Kedrion Biopharma ; For the post-exposure prophylaxis of rabies infection, Approved August 2017

Mavyret (glecaprevir and pibrentasvir) ; AbbVie; For the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6, Approved August 2017

Prevymis (letermovir) ; Merck; For the prevention of cytomegalovirus following allogenic hematopoietic stem cell transplant, Approved November 2017

Shingrix (Zoster Vaccine Recombinant, Adjuvanted) ; GlaxoSmithKline; For the prevention of herpes zoster (shingles), Approved October 2017

Solosec (secnidazole) ; Symbiomix Therapeutics; For the treatment of bacterial vaginosis , Approved September 2017

Vabomere (meropenem and vaborbactam); The Medicines Company; For the treatment of complicated urinary tract infections , Approved August 2017

Drugs Approved in 2016

Anthim (obiltoxaximab); Elusys Therapeutics; For the treatment of inhalational anthrax , Approved March 2016

Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April 2016

Epclusa (sofosbuvir and velpatasvir) ; Gilead Sciences; For the treatment of hepatitis C, Approved June 2016

Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as initial therapy, Approved March 2016

Syndros (dronabinol oral solution); Insys Therapeutics; For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy, Approved July 2016

Vaxchora (Cholera Vaccine, Live, Oral); PaxVax; For active immunization against Cholera, Approved June 2016

Vemlidy (tenofovir alafenamide); Gilead Sciences; For the treatment of chronic hepatitis B , Approved November 2016

Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016

Zinplava (bezlotoxumab); Merck; For the treatment of recurrent Clostridium difficile infection in patients receiving antibacterial treatment, Approved October 2016

Drugs Approved in 2015

Avycaz (ceftazidime-avibactam); Actavis; For the treatment of complicated intra-abdominal and urinary tract infections, Approved February 2015

Bexsero (Meningococcal Group B Vaccine); Novartis; For the treatment of invasive meningococcal disease caused by serogroup B, Approved January 2015

Cresemba (isavuconazonium sulfate) ; Astellas; For the treatment of invasive aspergillosis and invasive mucormycosis, Approved March 2015

Daklinza (daclatasvir) ; Bristol-Myers Squibb; For the treatment of chronic HCV genotype 3, Approved July 2015

Evotaz (atazanavir and cobicistat) ; Bristol-Myers Squibb; For the treatment of HIV-1 infection, Approved January 2015

Fluad (trivalent influenza vaccine); Seqirus; For the prevention of influenza A and B, Approved November 2015

Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 infection, Approved November 2015

Prezcobix (darunavir and cobicistat); Janssen; For the treatment of HIV-1 infection, Approved January 2015

Technivie, (ombitasvir, paritaprevir and ritonavir); Abbvie; For the treatment of chronic HCV genotype 4, Approved July 2015

Drugs Approved in 2014

Dalvance (dalbavancin); Durata Therapeutics; For the treatment of acute bacterial skin and skin structure infections, Approved May 2014

Harvoni (ledipasvir and sofosbuvir); Gilead; For the treatment of hepatitis C, Approved October 2014

Impavido (miltefosine); Knight Therapeutics; For the treatment of visceral, cutaneous and mucosal leishmaniasis, Approved March 2014

Jublia (efinaconazole) 10% topical gel; Valeant Pharmaceuticals; For the treatment of onychomycosis of the toenails, Approved June 2014

Kerydin (tavaborole); Anacor; For the treatment of onychomycosis of the toenails, Approved July 2014

Metronidazole 1.3% Vaginal Gel; Actavis, Inc.; For the treatment of bacterial vaginosis, Approved April 2014

Orbactiv (oritavancin); The Medicines Company; For the treatment of acute bacterial skin and skin structure infections, Approved August 2014

Rapivab (peramivir injection); Biocryst; For the treatment of acute uncomplicated influenza in adults, Approved December 2014

Sivextro (tedizolid phosphate) ; Cubist Pharmaceuticals; For the treatment of acute bacterial skin and skin structure infections, Approved June 2014

Triumeq (abacavir, dolutegravir, and lamivudine); ViiV HealthCare; For the treatment of HIV-1, Approved August 2014

Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir) tablets; Abbvie; For the treatment of genotype 1 chronic hepatitis C virus, Approved December 2014

Xtoro (finafloxacin otic suspension) 0.3%; Alcon; For the treatment of acute otitis externa, Approved December 2014

Zerbaxa (ceftolozane + tazobactam) ; Cubist Pharmaceuticals; For the treatment of complicated intra-abdominal and urinary tract infections, Approved December 2014

Drugs Approved in 2013

Flublok (seasonal influenza vaccine); Protein Sciences; For the active immunization against influenza virus subtypes A and type B, Approved January 2013

Luzu (luliconazole) Cream 1%; Valeant Pharmaceuticals; For the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis, November of 2013

Olysio (simeprevir); Janssen Therapeutics; For the treatment of hepatitis C, November of 2013

Sitavig (acyclovir) buccal tablets; BioAlliance Pharma; For the treatment of recurrent herpes labialis in adults, Approved April 2013

Sovaldi (sofosbuvir); Gilead Sciences; For the treatment of hepatitis C, December of 2013

VariZIG, Varicella Zoster Immune Globulin (Human); Cangene; For the post-exposure prophylaxis of varicella zoster (chickenpox), Approved January 2013

Vibativ (telavancin); Theravance; For the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus, Approved June 2013

Drugs Approved in 2012

Abthrax (raxibacumab); GlaxoSmithKline; For the treatment and prevention of anthrax, Approved December of 2012

Afinitor (everolimus); Novartis; For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex, Approved April 2012

Cystaran (cysteamine hydrochloride); Sigma Tau Pharmaceuticals; For the treatment of corneal cystine crystal accumulation due to cystinosis, Approved October 2012

Dymista (azelastine hydrochloride and fluticasone propionate); Meda Pharmaceuticals Inc; For the relief of symptoms of seasonal allergic rhinitis, Approved May 2012

Flucelvax, Influenza Virus Vaccine; Novartis; For the treatment of influenza virus subtypes A and type B, Approved November 2012

Jetrea (ocriplasmin); Thrombogenics; For the treatment of symptomatic vitreomacular adhesion, Approved October 2012

Linzess (linaclotide); Forest Labs and Ironwood Pharmaceuticals; For the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation, Approved August 2012

Mytesi (crofelemer); Napo Pharmaceuticals; For the treatment of non-infectious diarrhea in adults with HIV/AIDS, Approved December 2012

Qnasl (beclomethasone dipropionate) nasal aerosol; Teva Pharmaceutical; For the treatment of seasonal and perennial allergic rhinitis, Approved March 2012

Sirturo (bedaquiline); Janssen Therapeutics; For the treatment of multi-drug resistant tuberculosis, Approved December 2012

Sklice (ivermectin) lotion; Sanofi Pasteur; For the treatment of head lice, Approved February 2012

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate); Gilead; For the treatment of HIV-1 infection, Approved August 2012

Tudorza Pressair (aclidinium bromide inhalation powder); Forest Laboratories; For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, Approved July 2012

Drugs Approved in 2011

Afinitor (everolimus); Novartis; For the treatment of advanced pancreatic neuroendocrine tumors, Approved May 2011

Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate); Gilead; For the treatment of HIV-1 in treatment-naive adults, Approved August of 2011

Dificid (fidaxomicin); Optimer Pharmaceuticals; For the treatment of Clostridium difficile-associated diarrhea, Approved May 2011

Edurant (rilpivirine); Tibotec; For the treatment of HIV-1, Approved May 2011

Eylea (aflibercept); Regeneron Pharmaceuticals; For the treatment of neovascular (wet) age-related macular degeneration, Approved November 2011

Firazyr (icatibant); Shire Pharmaceuticals; For the treatment of acute attacks of hereditary angioedema, Approved August of 2011

Gralise (gabapentin); Abbott Laboratories; For the treatment of postherpetic neuralgia, Approved February 2011

Incivek (telaprevir); Vertex Pharmaceuticals; For the treatment of genotype 1 chronic hepatitis C, Approved May 2011

Victrelis (boceprevir); Merck; For the treatment of chronic hepatitis C genotype 1, Approved May 2011

Drugs Approved in 2010

Egrifta (tesamorelin for injection); Theratechnologies; For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, Approved November 2010

Menveo (meningitis vaccine); Novartis; For the active immunization to prevent invasive meningococcal disease, Approved February 2010

Teflaro (ceftaroline fosamil); Cerexa; For the treatment of bacterial skin infections and bacterial pneumonia, November 2010

Zymaxid (gatifloxacin ophthalmic solution); Allergan; For the treatment of bacterial conjunctivitis, Approved May 2010

Drugs Approved in 2009

Afinitor (everolimus); Novartis; For the treatment of renal cell carcinoma, Approved March 2009

Bepreve (bepotastine besilate ophthalmic solution); Ista Pharmaceuticals; For the treatment of itching associated with allergic conjunctivitis, Approved September 2009

Hiberix (Haemophilus b Conjugate Vaccine; Tetanus Toxoid Conjugate); GlaxoSmithKline; For the prevention of invasive disease caused by Haemophilus influenzae type b., August of 2009

Vibativ (telavancin); Theravance; For the treatment of complicated skin and skin structure infections, Approved September 2009

Drugs Approved in 2008

Aptivus (tipranavir); Boehringer Ingelheim; For the treatment of HIV, Approved June 2008

Astepro (azelastine hydrochloride nasal spray); Meda Pharmaceuticals Inc; For the treatment of seasonal and perennial allergic rhinitis, Approved October 2008

Intelence (etravirine); Tibotec; For the treatment of HIV-1, Approved January 2008

Patanase (olopatadine hydrochloride); Alcon; For the treatment of seasonal allergic rhinitis, Approved April 2008

Viread (tenofovir disoproxil fumarate); Gilead; For the treatment of hepatitis B, Approved August 2008

Drugs Approved in 2007

Isentress (raltegravir); Merck; For the treatment of HIV-1, Approved October 2007

Selzentry (maraviroc); Pfizer; For the treatment of CCR5-tropic HIV-1, Approved August 2007

Veramyst (fluticasone furoate); GlaxoSmithKline; For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007

Xyzal (levocetirizine dihydrochloride); UCB; For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007

Drugs Approved in 2006

Eraxis (anidulafungin); Pfizer; For the treatment of Candida fungal infections, Approved February 2006

Noxafil (posaconazole); Schering-Plough; For the treatment of fungal infections, Approved in September 2006

Prezista (darunavir); Tibotec; For the treatment of treatment-resistant HIV infections, Approved June 2006

Tyzeka (telbivudine); Idenix Pharma; For the treatment of hepatitis B virus, Approved October 2006

Veregen (kunecatechins); Medigene; For the treatment of external genital and perianal warts, Approved October 2006

Drugs Approved in 2005

Aptivus (tipranavir); Boehringer Ingelheim; For the adjunctive treatment of HIV-1 infections, Approved June, 2005

Baraclude (entecavir); Bristol-Myers Squibb; For the treatment of chronic hepatitis B infections with evidence of active viral replication, Approved March, 2005

Drugs Approved in 2003

FluMist ( Influenza Virus Vaccine); MedImmune; For the prevention of disease caused by influenza A and B viruses, Approved June 2003

Fuzeon (enfuvirtide); Trimeris, Roche; For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved March 2003

Lexiva (fosamprenavir calcium); GlaxoSmithKline; For the treatment of HIV infection in adults in combination with other antiretroviral agents., Approved October 2003

Reyataz (atazanavir sulfate); Bristol-Myers Squibb; For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved July 2003

Drugs Approved in 2002

Botox Cosmetic (botulinum toxin type A); Allergan; For the temporary improvement in the appearance of glabellar lines (brow furrow), Approved April 2002

Clarinex; Schering-Plough; Once-daily oral tablet for the treatment of allergic rhinitis and chronic ideopathic urticaria, Approved February 2002

Hepsera (adefovir dipivoxil); Gilead; For the treatment of chronic hepatitis B in adults with evidence of active viral replication, Approved September 2002

Pediarix Vaccine; GlaxoSmithKline; For the prevention of diphtheria, tetanus, pertussi, polio and hepatitis B in children 6 weeks to 7 years old., Approved December 2002

Pegasys (peginterferon alfa-2a); Roche; For the treatment of chronic hepatitis C who have compensated liver disease, Approved October 2002

Sustiva; Bristol-Myers Squibb; Once-daily oral tablet for the the treatment of HIV infection, Approved February 2002

Vfend (voriconazole); Pfizer; For the treatment of fungal infections, Approved May 2002

Zelnorm (tegaserod maleate) Tablets; Novartis; For the short-term treatment of irritable bowel syndrome in women whose primary bowel symptom is constipation, Approved July 2002

Drugs Approved in 2001

Avelox I.V. (moxifloxacin hydrochloride); Bayer; Injectable antibacterial agent for adults with susceptible strains of bacterial infections, Approved November 2001

Cancidas; Merck; Intravenous infusion for the treatment of invasive aspergillosis, Approved January 2001

Invanz; Merck; Once-daily injectable treatment for bacterial infections, Approved November 2001

Lamisil Solution, 1%; Novartis; Topical treatment for tinea (pityriasis) versicolor, althete's foot, jock itch, and ringworm, Approved March 2001

NasalCrom Nasal Spray; Pharmacia & Upjohn; Over-the-counter nasal spray for treatment of all nasal allergy symptoms, Approved April 2001

Peg-Intron (peginterferon alfa-2b); Schering-Plough; For the treatment of chronic hepatitis C, Approved January 2001

Rebetol (ribavirin); Schering-Plough; For the treatment of chronic hepatitis C, Approved July 2001

Spectracef; TAP Pharmaceuticals; Oral tablets for the treatment of mild to moderate bacterial infections, Approved August 2001

Tavist (clemastine fumarate); Novartis; Oral tablet for temporary relief of symptoms associated with hay fever, allergic rhinitis, and the common cold, Approved March 2001

Twinrix; GlaxoSmithKline; For the prevention of hepatitis A and B, Approved May 2001

Valcyte (valganciclovir HCl); Roche; For the treatment of cytomegalovirus retinitis in patients with AIDS, Approved March 2001

Viread (tenofovir disoproxil fumarate); Gilead; Once-daily oral tablet for the treatment of human immunodeficiency virus (HIV) infection, Approved October 2001

Xigris (drotrecogin alfa [activated]); Eli Lilly; For the treatment of severe sepsis, Approved November 2001

Drugs Approved in 2000

ABREVA (docosanol); AVANIR PHARMACEUTICALS; Cold sore/fever blister, Approved July 2000

Cefazolin and Dextrose USP; B Braun Medical; Respiratory tract infections, Approved July 2000

Children's Motrin Cold; McNeil Consumer Products; For temporary relief of the common cold, Approved August 2000

Kaletra Capsules and Oral Solution; Abbott Laboratories; For the treatment of HIV-1 infection, Approved September 2000

Lamisil (terbinafine hydrochloride) Solution, 1%; Novartis; For the treatment of athlete's foot, jock itch and ringworm, Approved March 2000

Lotrisone (clotrimazole/betamethasone diproprionate) lotion; Schering-Plough; For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis, Approved December 2000

Lotronex (alosetron HCL) Tablets; GlaxoSmithKline; Indicated for Irritable Bowel Syndrome (IBS) in females with diarrhea-predominant IBS, Approved February 2000

Tri-Nasal Spray (triamcinolone acetonide spray); Muro Pharmaceutical; For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older, Approved February 2000

Trizivir (abacavir sulfate; lamivudine; zidovudine AZT) Tablet; GlaxoSmithKline; For the treatment of HIV-1 infection, Approved November 2000

Drugs Approved in 1999

Nasonex Nasal Spray; Schering-Plough; Treatment of seasonal allergic rhinitis, Approved January 1999

Rhinocort Aqua Nasal Spray; AstraZeneca; A nasal spray containing budesonide, Approved October 1999

Synercid I.V.; Rhone Poulenc Rorer; quinupristin and dalfopristin for injection, Approved September 1999

Tamiflu capsule; Roche; Oseltamivir phosphate capsule, October 27, 1999

Drugs Approved in 1998

Allegra-D; Hoechst Marion Roussel; Treatment for nasal congestion due to seasonal allergy, Approved March 1998

Clemastine fumarate syrup; Morton Grove Pharmaceuticals; Generic equivalent of Tavist Syrup, Approved March 1998

REBETRON (TM) Combination Therapy; Schering-Plough; Treatment for Chronic Hepatitis C, Approved June 1998

Synagis; MedImmune; Treatment for the prevention of serious lower respiratory tract disease in infants, Approved June 1998

Viroptic; King Pharmaceuticals; Treatment for inflammation of the cornea in children due to herpes simplex virus, Approved February 1998

Drugs Approved in 1997

Aldara (imiquimod); 3M Pharmaceuticals; Treatment for external genital and perianal warts, Approved March 1997

Bactroban Cream; SmithKline Beecham; Treatment for secondarily infected traumatic skin lesions, Approved December 1997

Ceftin (cefuroxime axetil); GlaxoSmithKline; Treatment of secondary bacterial infections of acute bronchitis, Approved September 1997

Claritin RediTabs (10 mg loratadine rapidly-disintegrating tablet); Schering-Plough; Treatment for seasonal allergy symptoms, Approved January 1997

Combivir; GlaxoSmithKline; Treatment for AIDS and HIV Infection, Approved September 1997

Condylox Gel 0.5% (pokofilox); Oclassen Pharmaceuticals; Treatment for external genital and perianal warts, Approved March 1997

Famvir (famciclovir); SmithKline Beecham; Treatment for genital herpes, Approved September 17, 1997

Flonase Nasal Spray; GlaxoSmithKline; Treatment for seasonal and perennial allergic rhinitis, Approved November 1997

Floxin otic; Daiichi Sankyo; Treatment for otitis media, Approved December 1997

Fortovase; Roche; Treatment for HIV infection, Approved November 1997

INFERGEN (interferon alfacon-1); Amgen; Treatment for chronic hepatitis C virus, Approved October 1997

Intron A (interferon alfa-2b, recombinant); Schering-Plough; Treatment for hepatitis C, Approved March 1997

Mentax (1% butenafine HCl cream); Penederm; Treatment for athlete's foot, Approved December 1997

Mentax (1% butenafine HCl cream); Penederm; Treatment for tinea corporis (ringworm) and tinea cruris (groin fungus), Approved January 1997

Norvir (ritonavir); Abbott Laboratories; Treatment for HIV infection, Approved March 1996/March 1997

Omnicef; Warner-Lambert; Treatment against various bacterias, Approved December 1997

Rescriptor Tablets (delavirdine mesylate tablets); Pharmacia & Upjohn; Treatment for HIV-1 infection, Approved April 1997

Taxol; Bristol-Myers Squibb; Treatment for AIDS-related Kaposi's Sarcoma, Approved August 1997

Timentin; SmithKline Beecham; Treatment for septicemia, Approved December 1997

Trovan; Pfizer; Treatment for bacterial infections, Approved December 1997

VIRACEPT (nelfinavir mesylate); Agouron Pharmaceuticals; Treatment for HIV infection in adults and children, Approved March 1997

Zerit (stavudine); Bristol-Myers Squibb; Treatment for infants and children infected with HIV, Approved January 1997

Drugs Approved in 1996

AK-Con-A (naphazoline ophthalmic); Akorn; Over-the-counter combination vasoconstrictor/antihistamine product for opthalmic use, Approved January 1996

Allegra (fexofenadine hydrochloride); Hoechst Marion Roussel; Treatment for seasonal allergy symptoms, Approved July 1996

Astelin nasal spray; Wallace Laboratories; Treatment for seasonal allergic rhinitis, Approved November 1996

Atrovent (ipratropium bromide); Boehringer Ingelheim; Treatment for runny nose due to allergies and the common cold, Approved January 1996

Augmentin (amoxicillin/clavulanate); SmithKline Beecham; Treatment for infections involving drug-resistant bacteria, Approved February 1996

Children's Advil (pediatric ibuprofen); Whitehall-Robins Healthcare; Treatment of fever and minor aches and pains, Approved July 1996

Confide; Johnson & Johnson; HIV testing and counseling service, Approved May 1996

Crixivan (Indinavir sulfate); Merck; Treatment for HIV infection, Approved March 1996

Elmiron (pentosan polysulfate sodium); IVAX; Treatment for interstitial cystitis, Approved October 1996

Havrix; SmithKline Beecham; Treatment for hepatitis A, Approved March 1996

IvyBlock; EnviroDerm Pharmaceuticals; Treatment for poison ivy, poison oak, and poison sumac, Approved September 1996

Lamisil (terbinafine hydrochloride) Tablets; Sandoz Pharmaceuticals; Treatment for nail fungal infections, Approved May 1996

Leukine (sargramostim); Immunex; Treatment for the replenishment of white blood cells, Approved November 1996

Merrem I.V. (meropenem); AstraZeneca; Treatment for intra-abdominal infections and bacterial meningitis, Approved June 1996

Nasacort AQ (triamcinolone acetonide) Nasal Spray; Rhone Poulenc Rorer; Treatment for allergic rhinitis, Approved May 1996

OcuHist; Pfizer; Over-the-counter antihistamine eye drop, Approved January 1996

RespiGam (Respiratory Syncitial Virus Immune Globulin Intravenous); MedImmune; Treatment for the prevention of respiratory syncytial virus disease, Approved January 1996

Tavist (clemastine fumarate); Sandoz Pharmaceuticals; Treatment for cold symptoms, Approved November 1996

Vancenase AQ 84 mcg Double Strength; Schering-Plough; Treatment for allergic and non-allergic rhinitis, Approved June 1996

Videx (didanosine); Bristol-Myers Squibb; Treatment of HIV infection, Approved June 1996

Viramune (nevirapine); Boehringer Ingelheim; Treatment for HIV infection, Approved June 1996

Zithromax (azithromycin); Pfizer; Treatment for Mycobacterium avium complex (MAC) in subjects with advanced HIV infection, Approved June 1996

Drugs Approved in 1995

Cedax (ceftibuten); Schering-Plough; Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis, Approved December 1995

Clarithromycin (Biaxin); Abbott Laboratories; Treatment for the prevention of disseminated Mycobacterium avium complex (MAC), Approved December 1995

Epivir (lamivudine); GlaxoSmithKline; Treatment used in combination with AZT for AIDS/HIV infection, Approved on November 17, 1995

Invirase (saquinavir); Roche; Treatment for HIV/AIDS, Approved on December 7, 1995

Valtrex (valacyclovir HCl); GlaxoSmithKline; Treatment for recurrent genital herpes, Approved December 1995

Western blot confirmatory device; Epitope; Confirmatory test for HIV, Approved in December 1995

Zerit (stavudine); Bristol-Myers Squibb; Treatment for HIV-infected adults who are intolerant of approved therapies, Approved December 22, 1995

Zyrtec (cetirizine HCl); Pfizer; Treatment for year-round allergies, seasonal allergic rhinitis, and chronic itching and hives, Approved December 1995